Drug recall · April 6, 2022
Glycopyrrolate Tablets recall
Why: Presence of Foreign Substance: Complaint for pieces of glass discovered in a sealed bottle which came from equipment within the packaging room.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Glycopyrrolate Tablets, USP, 1 mg, 100-count bottle, Rx Only, Distributed by: Aurobindo Pharma USA, Inc., 279 Princeton-Hightstown Road, East Windsor, NJ 08520, NDC 13107-014-01.
- Lots / codes
Lot: 01421008A1, Exp 03/2023
- Quantity
- 4080 bottles
- Company
- Aurolife Pharma, LLC, Dayton, NJ
- Distribution
- Nationwide in the USA and Puerto Rico
- Initiated
- March 17, 2022 · Voluntary: Firm initiated
- Classified
- March 30, 2022
- Reported
- April 6, 2022
- Ended
- March 25, 2024
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Glycopyrronium
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.